Specialized antibody platforms ADL offers proprietary libraries (ALTHEA Gold, Super Naive OPAL, MIM) and phage-display and yeast-display solutions, presenting multiple cross-sell opportunities to therapeutic and diagnostic researchers seeking diverse discovery platforms.

End-to-end service model From library construction and screening to expression and characterization, ADL provides integrated services that can be pitched to clients looking to streamline discovery workflows and shorten development timelines.

Rising yeast-display niche In addition to established phage-display expertise, ADL expanding into yeast-display solutions creates a foothold in a growing segment, enabling sales conversations with teams exploring alternative display technologies.

Global leadership signals trust Position ADL as a premier partner for translational research due to its global leadership in display reagents, which can unlock collaborations, grants, and contract opportunities with larger biotech and pharma players.

Growth and scale hints Revenue in the lower-mid range and a small team imply high potential for scalable service-based contracts, technology licensing, and strategic partnerships to expand capacity without significant overhead.